Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies
Table 2
Stratified analysis of safety outcomes according to anticoagulant mechanism.
Number of reports
Pooled RR (95% CI)
value
(%)
Major bleeding
Overall estimation
10
0.75 (0.63-0.90)
0.002
94
Anti-IIa agents
2
0.58 (0.52-0.64)
<0.0001
0
Anti-Xa agents
8
0.81 (0.66-0.99)
0.044
95
Intracranial hemorrhage
Overall estimation
13
0.50 (0.44-0.56)
<0.0001
22
Anti-IIa agents
3
0.39 (0.31-0.49)
<0.0001
0
Anti-Xa agents
10
0.52 (0.47-0.59)
<0.0001
0
Major gastrointestinal bleeding
Overall estimation
12
0.77 (0.62-0.95)
0.016
93
Anti-IIa agents
3
0.64 (0.49-0.83)
0.001
66
Anti-Xa agents
9
0.83 (0.64-1.07)
0.15
94
Anti-IIa agents include dabigatran. Anti-Xa agents include apixaban, edoxaban, and rivaroxaban. CI: confidence interval, RR: relative risk.
